21
TITLE: Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up  Full Text
AUTHORS: Wirth, M; Tyrrell, C; Delaere, K; Sanchez Chapado, M; Ramon, J; Wallace, DMA; Hetherington, J; Pina, F; Heyns, CF; Navani, S; Armstrong, J;
PUBLISHED: 2007, SOURCE: PROSTATE CANCER AND PROSTATIC DISEASES, VOLUME: 10, ISSUE: 1
INDEXED IN: Scopus WOS CrossRef
22
TITLE: Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme  Full Text
AUTHORS: Wirth, M; Tyrrell, C; Delaere, K; Sanchez Chapado, M; Ramon, J; Wallace, DMA; Hetherington, J; Pina, F; Heyns, C; Borchers, T; Morris, T; Armstrong, J;
PUBLISHED: 2005, SOURCE: PROSTATE CANCER AND PROSTATIC DISEASES, VOLUME: 8, ISSUE: 2
INDEXED IN: Scopus WOS CrossRef
23
TITLE: Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression  Full Text
AUTHORS: Wirth, M; Tyrrell, C; Wallace, M; Delaere, KP; Sanchez Chapado, M; Ramon, J; Hetherington, J; Pina, F; Heynes, CF; Borchers, TM; Morris, T; Stone, A;
PUBLISHED: 2001, SOURCE: UROLOGY, VOLUME: 58, ISSUE: 2
INDEXED IN: Scopus WOS CrossRef
Page 3 of 3. Total results: 23.